Vallejo-Vaz A.J.Kondapally Seshasai S.R.Cole D.Hovingh G.K.Kastelein J.J.P.Mata P.Raal F.J.Santos R.D.Soran H.Watts G.F.Abifadel M.Aguilar-Salinas C.A.Akram A.Alnouri F.Alonso R.Al-Rasadi K.Banach M.Bogsrud M.P.Bourbon M.Bruckert E.Car J.Corral P.Descamps O.Dieplinger H.Durst R.Freiberger T.Gaspar I.M.Genest J.Harada-Shiba M.Jiang L.Kayikcioglu M.Lam C.S.P.Latkovskis G.Laufs U.Liberopoulos E.Nilsson L.Nordestgaard B.G.O'Donoghue J.M.Sahebkar A.Schunkert H.Shehab A.Stoll M.TA-CHEN SUSusekov A.Wid?n E.Catapano A.L.Ray K.K.2020-09-282020-09-2820150021-9150https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942509791&doi=10.1016%2fj.atherosclerosis.2015.09.021&partnerID=40&md5=2cce56eb4c6798315543236bb5549539https://scholars.lib.ntu.edu.tw/handle/123456789/514775[SDGs]SDG3Article; disease registry; Europe; familial hypercholesterolemia; health program; human; medical society; prevalence; priority journal; genetics; health; heterozygote; Hyperlipoproteinemia Type II; mutation; low density lipoprotein receptor; Europe; Global Health; Heterozygote; Humans; Hyperlipoproteinemia Type II; Mutation; Receptors, LDL; Societies, Medicaljournal article10.1016/j.atherosclerosis.2015.09.021264089302-s2.0-84942509791